vs
Side-by-side financial comparison of EMCOR Group, Inc. (EME) and Zoetis (ZTS). Click either name above to swap in a different company.
EMCOR Group, Inc. is the larger business by last-quarter revenue ($4.6B vs $2.3B, roughly 2.0× Zoetis). Zoetis runs the higher net margin — 26.6% vs 6.6%, a 20.0% gap on every dollar of revenue. On growth, EMCOR Group, Inc. posted the faster year-over-year revenue change (19.7% vs 2.9%). Over the past eight quarters, EMCOR Group, Inc.'s revenue compounded faster (12.3% CAGR vs -2.1%).
EMCOR Group, Inc., is an engineering, construction, and property management company headquartered in Norwalk, Connecticut.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
EME vs ZTS — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $4.6B | $2.3B |
| Net Profit | $305.5M | $601.0M |
| Gross Margin | 18.7% | 71.7% |
| Operating Margin | 8.7% | — |
| Net Margin | 6.6% | 26.6% |
| Revenue YoY | 19.7% | 2.9% |
| Net Profit YoY | 26.9% | -0.2% |
| EPS (diluted) | $6.84 | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $4.6B | $2.3B | ||
| Q4 25 | $4.5B | $2.4B | ||
| Q3 25 | $4.3B | $2.4B | ||
| Q2 25 | $4.3B | $2.5B | ||
| Q1 25 | $3.9B | $2.2B | ||
| Q4 24 | $3.8B | $2.3B | ||
| Q3 24 | $3.7B | $2.4B | ||
| Q2 24 | $3.7B | $2.4B |
| Q1 26 | $305.5M | $601.0M | ||
| Q4 25 | $434.6M | $603.0M | ||
| Q3 25 | $295.4M | $721.0M | ||
| Q2 25 | $302.2M | $718.0M | ||
| Q1 25 | $240.7M | $631.0M | ||
| Q4 24 | $292.2M | $581.0M | ||
| Q3 24 | $270.3M | $682.0M | ||
| Q2 24 | $247.6M | $624.0M |
| Q1 26 | 18.7% | 71.7% | ||
| Q4 25 | 19.7% | 70.2% | ||
| Q3 25 | 19.4% | 71.5% | ||
| Q2 25 | 19.4% | 73.6% | ||
| Q1 25 | 18.7% | 72.0% | ||
| Q4 24 | 20.1% | 69.5% | ||
| Q3 24 | 19.9% | 70.6% | ||
| Q2 24 | 18.7% | 71.7% |
| Q1 26 | 8.7% | — | ||
| Q4 25 | 12.7% | 31.9% | ||
| Q3 25 | 9.4% | 37.0% | ||
| Q2 25 | 9.6% | 36.7% | ||
| Q1 25 | 8.2% | 36.5% | ||
| Q4 24 | 10.3% | 31.6% | ||
| Q3 24 | 9.8% | 36.6% | ||
| Q2 24 | 9.1% | 33.0% |
| Q1 26 | 6.6% | 26.6% | ||
| Q4 25 | 9.6% | 25.3% | ||
| Q3 25 | 6.9% | 30.0% | ||
| Q2 25 | 7.0% | 29.2% | ||
| Q1 25 | 6.2% | 28.4% | ||
| Q4 24 | 7.7% | 25.1% | ||
| Q3 24 | 7.3% | 28.6% | ||
| Q2 24 | 6.8% | 26.4% |
| Q1 26 | $6.84 | $1.42 | ||
| Q4 25 | $9.64 | $1.37 | ||
| Q3 25 | $6.57 | $1.63 | ||
| Q2 25 | $6.72 | $1.61 | ||
| Q1 25 | $5.26 | $1.41 | ||
| Q4 24 | $6.30 | $1.29 | ||
| Q3 24 | $5.80 | $1.50 | ||
| Q2 24 | $5.25 | $1.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $916.4M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.9B | — |
| Total Assets | $9.5B | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $916.4M | — | ||
| Q4 25 | $1.1B | — | ||
| Q3 25 | $655.1M | $2.1B | ||
| Q2 25 | $486.0M | $1.4B | ||
| Q1 25 | $576.7M | $1.7B | ||
| Q4 24 | $1.3B | $2.0B | ||
| Q3 24 | $1.0B | $1.7B | ||
| Q2 24 | $807.3M | $1.6B |
| Q1 26 | $3.9B | — | ||
| Q4 25 | $3.7B | $3.3B | ||
| Q3 25 | $3.3B | $5.4B | ||
| Q2 25 | $3.1B | $5.0B | ||
| Q1 25 | $2.9B | $4.7B | ||
| Q4 24 | $2.9B | $4.8B | ||
| Q3 24 | $2.8B | $5.2B | ||
| Q2 24 | $2.7B | $5.0B |
| Q1 26 | $9.5B | — | ||
| Q4 25 | $9.3B | $15.5B | ||
| Q3 25 | $8.6B | $15.2B | ||
| Q2 25 | $8.4B | $14.5B | ||
| Q1 25 | $8.1B | $14.1B | ||
| Q4 24 | $7.7B | $14.2B | ||
| Q3 24 | $7.3B | $14.4B | ||
| Q2 24 | $7.1B | $14.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $558.0K | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 0.00× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $558.0K | — | ||
| Q4 25 | $524.4M | $893.0M | ||
| Q3 25 | $475.5M | $938.0M | ||
| Q2 25 | $193.7M | $486.0M | ||
| Q1 25 | $108.5M | $587.0M | ||
| Q4 24 | $469.5M | $905.0M | ||
| Q3 24 | $526.4M | $951.0M | ||
| Q2 24 | $279.7M | $502.0M |
| Q1 26 | — | — | ||
| Q4 25 | $492.5M | $732.0M | ||
| Q3 25 | $448.8M | $805.0M | ||
| Q2 25 | $165.6M | $308.0M | ||
| Q1 25 | $82.3M | $438.0M | ||
| Q4 24 | $451.8M | $689.0M | ||
| Q3 24 | $508.7M | $784.0M | ||
| Q2 24 | $260.4M | $370.0M |
| Q1 26 | — | — | ||
| Q4 25 | 10.9% | 30.7% | ||
| Q3 25 | 10.4% | 33.5% | ||
| Q2 25 | 3.8% | 12.5% | ||
| Q1 25 | 2.1% | 19.7% | ||
| Q4 24 | 12.0% | 29.7% | ||
| Q3 24 | 13.8% | 32.8% | ||
| Q2 24 | 7.1% | 15.7% |
| Q1 26 | — | — | ||
| Q4 25 | 0.7% | 6.7% | ||
| Q3 25 | 0.6% | 5.5% | ||
| Q2 25 | 0.7% | 7.2% | ||
| Q1 25 | 0.7% | 6.7% | ||
| Q4 24 | 0.5% | 9.3% | ||
| Q3 24 | 0.5% | 7.0% | ||
| Q2 24 | 0.5% | 5.6% |
| Q1 26 | 0.00× | — | ||
| Q4 25 | 1.21× | 1.48× | ||
| Q3 25 | 1.61× | 1.30× | ||
| Q2 25 | 0.64× | 0.68× | ||
| Q1 25 | 0.45× | 0.93× | ||
| Q4 24 | 1.61× | 1.56× | ||
| Q3 24 | 1.95× | 1.39× | ||
| Q2 24 | 1.13× | 0.80× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EME
Segment breakdown not available.
ZTS
| Companion Animal | $1.5B | 67% |
| Livestock | $720.0M | 32% |
| Contract Manufacturing & Human Health | $23.0M | 1% |
